Investigator Initiated Extended Clinical Trial (R01 Clinical Trial Required)
ID: 345365Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/345365

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-23-084.html
Timeline
    Description

    The National Institutes of Health (NIH) has announced a Funding Opportunity Announcement (FOA) titled "Investigator Initiated Extended Clinical Trial (R01 Clinical Trial Required)," inviting applications for long-term clinical trials lasting 6 to 7 years. These trials must be hypothesis-driven and align with the research objectives of the participating institutes, with no limitations on application budgets, although they must reflect the project's needs. This initiative is crucial for advancing clinical research and enhancing public health through well-supported extended trials. Interested applicants can find more information and submission guidelines at the provided link, with applications due by January 13, 2026. For inquiries, contact NIH Grants Information at grantsinfo@nih.gov.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-23-084.html
    The Department of Health and Human Services, through the National Institutes of Health (NIH), has released a Funding Opportunity Announcement (FOA) titled "Investigator Initiated Extended Clinical Trial (R01 Clinical Trial Required)." This funding initiative invites applications for long-term clinical trials, lasting 6 to 7 years, that are hypothesis-driven and align with the research objectives of participating institutes. There are no limitations on application budgets, but they must reflect project needs, and applicants are encouraged to consult NIH staff before submission. Eligible organizations include various educational institutions, nonprofits, and government entities. The application process involves strict adherence to detailed submission guidelines, including a required milestone plan and comprehensive clinical protocol. The review process evaluates multiple criteria such as significance, innovation, approach, and the investigators’ qualifications. This initiative underscores NIH's commitment to advancing clinical research and enhancing public health through well-supported, extended clinical trials. Submissions are due by specified deadlines, and compliance with all application instructions is critical to avoid disqualification from review.
    Similar Opportunities
    Research Project Grant (Parent R01 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a Research Project Grant (Parent R01 Clinical Trial Required) to support specified clinical research projects that align with the missions of various NIH institutes. Applicants are required to propose at least one clinical trial, focusing on significant health-related research areas, and must comply with the NIH Grants Policy Statement. This funding opportunity is crucial for advancing medical science and improving patient care, emphasizing innovation and scientific merit in addressing important health issues. The application deadline is January 7, 2025, and interested parties can reach out to the NIH OER Webmaster at FBOWebmaster@OD.NIH.GOV for further inquiries. More details can be found at the provided link: http://grants.nih.gov/grants/guide/pa-files/PA-20-183.html.
    NIAID Clinical Trial Implementation Cooperative Agreement (U01 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a Notice of Funding Opportunity (NOFO) for the NIAID Clinical Trial Implementation Cooperative Agreement (U01), aimed at supporting high-risk clinical trials that enhance the understanding of human diseases. This funding opportunity encourages applications for investigator-initiated, milestone-driven clinical trials, with each application permitted to propose only one clinical trial that must demonstrate a hypothesis-driven approach. The initiative emphasizes the importance of mechanistic studies within clinical trials and requires a robust plan for managing trial complexity and participant safety. Interested applicants can find additional details and guidelines at the provided NIH link, with the earliest submission date set for April 12, 2024, and the application deadline on January 13, 2027. For inquiries, applicants may contact NIH Grants Information at grantsinfo@nih.gov.
    NIA Multi-site Clinical Trial Implementation Grant (R01 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute on Aging (NIA), has announced the NIA Multi-site Clinical Trial Implementation Grant (R01 Clinical Trial Required) to support the implementation of investigator-initiated multi-site interventional clinical trials focused on aging research. These trials must be hypothesis-driven and aim to address significant health challenges faced by populations aged 65 and older, particularly concerning multimorbidity and polypharmacy. This funding opportunity is crucial for advancing scientific understanding and improving health outcomes for older adults, with applications accepted for new, renewal, and resubmission proposals, and no budget limits as long as they align with project needs. Interested applicants can find more information and submit their proposals by January 7, 2026, and should direct inquiries to grantsinfo@nih.gov.
    Single-Site Investigator-Initiated Clinical Trials (R61/R33 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Heart, Lung, and Blood Institute (NHLBI), has announced a funding opportunity for Single-Site Investigator-Initiated Clinical Trials (R61/R33), aimed at supporting applications for clinical trials that test therapeutic, behavioral, or prevention strategies relevant to NHLBI's mission. This funding mechanism involves a bi-phasic award structure, with an initial R61 phase focused on protocol development followed by an R33 phase for trial execution, emphasizing comprehensive project management, subject recruitment, and community engagement. The initiative is particularly significant for advancing clinical research while promoting diversity among study participants and project teams. Interested applicants can find more details and submit proposals by September 12, 2025, and should direct inquiries to the NIH OER Webmaster at OERWebmaster03@od.nih.gov.
    NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required) to support innovative research projects at the preliminary or conceptual stage, particularly those with the potential to advance biomedical, behavioral, or clinical research. Applicants must include at least one clinical trial in their proposals, focusing on mechanistic studies that align with the scientific missions of participating NIH Institutes and Centers. This funding opportunity is crucial for stimulating novel research that challenges conventional methods and improves clinical practices, with a maximum budget of $275,000 available for a two-year project, and no more than $200,000 allocated in any single year. Interested applicants should adhere to strict submission guidelines and can contact the NIH OER Webmaster at FBOWebmaster@OD.NIH.GOV for assistance; the application deadline is January 7, 2025.
    NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed) to support discrete scientific projects aligned with the interests of various NIH Institutes and Centers. This grant is specifically designed for projects that do not involve clinical trials, focusing instead on advancing health-related research and development. Eligible applicants include a wide range of organizations such as higher education institutions, nonprofits, and tribal governments, with no fixed budget limits, although applicants must justify their requested funding. Interested parties should note that the application deadline is January 7, 2025, and can find more information by contacting the NIH OER Webmaster at FBOWebmaster@OD.NIH.GOV or visiting the official announcement at http://grants.nih.gov/grants/guide/pa-files/PA-20-185.html.
    NIAID SBIR Phase II Clinical Trial Implementation Cooperative Agreement (U44 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the NIAID SBIR Phase II Clinical Trial Implementation Cooperative Agreement (FON PAR-24-099) aimed at small business concerns proposing investigator-initiated clinical trials that align with the NIAID's research mission. This program supports hypothesis-driven and milestone-driven clinical trials, particularly those classified as high-risk, which may involve unique interventions or the use of licensed products for unapproved indications. The initiative underscores the government's commitment to advancing innovative clinical research to address significant healthcare challenges, with funding of up to $1 million annually available for meritorious applications. Interested applicants must adhere to strict guidelines and submit their applications by the various deadlines, with the first due date on April 12, 2024, and the final deadline on January 13, 2027. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    NINDS Exploratory Clinical Trials (UG3/UH3 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute of Neurological Disorders and Stroke (NINDS), is offering a funding opportunity for investigator-initiated exploratory clinical trials under the UG3/UH3 mechanism. This initiative aims to support Phase 1 and Phase 2 clinical trials that address critical questions related to neurological disorders, focusing on studies involving drugs, biologics, devices, and early interventions. The program emphasizes rigorous research design and encourages diverse and innovative research teams, with grants potentially spanning up to five years, beginning with a planning phase before transitioning to execution. Interested applicants can find more information and application details at the provided link, with a submission deadline of March 10, 2025, and no cost-sharing or matching requirement.
    Clinical Trial Readiness for Rare Diseases, Disorders, and Syndromes (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the Clinical Trial Readiness for Rare Diseases, Disorders, and Syndromes (R21 Clinical Trial Not Allowed) grant. This funding opportunity aims to support projects that address critical needs for clinical trial readiness in rare diseases, specifically by facilitating the development of biomarkers and clinical outcome measures essential for trial design. The initiative is particularly important for advancing research on diseases affecting fewer than 200,000 individuals in the U.S., enhancing the likelihood of successful clinical trials. Applicants can request up to $275,000 over two years, with a submission deadline of October 17, 2024. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-23-159.html.
    Ancillary Studies to Ongoing Clinical Projects (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the Ancillary Studies to Ongoing Clinical Projects funding opportunity (PAR-23-025), aimed at supporting time-sensitive ancillary studies that enhance scientific knowledge related to the mission of the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). These studies must utilize existing cohorts, data, and biological samples to explore novel research questions that extend beyond the scope of the parent projects, with an emphasis on collaboration between junior and senior researchers. Grants may provide up to $300,000 per year for a duration of up to four years, with applications accepted until December 6, 2025. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.